[
    [
        {
            "time": "",
            "orginal_text": "2021年医药行业如何投资？高瓴A股医药公司持仓曝光",
            "features": {
                "keywords": [
                    "高瓴",
                    "A股",
                    "医药",
                    "持仓"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "original_text": "2021年医药行业如何投资？高瓴A股医药公司持仓曝光",
            "scores": {
                "News_content": "2021年医药行业如何投资？高瓴A股医药公司持仓曝光",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "orginal_text": "泰格医药(03347.HK)：2020年A股员工持股计划完成非交易过户",
            "features": {
                "keywords": [
                    "泰格医药",
                    "员工持股",
                    "非交易过户"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "original_text": "泰格医药(03347.HK)：2020年A股员工持股计划完成非交易过户",
            "scores": {
                "News_content": "泰格医药(03347.HK)：2020年A股员工持股计划完成非交易过户",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "orginal_text": "泰格医药(300347.SZ)：2020年A股员工持股计划完成非交易过户",
            "features": {
                "keywords": [
                    "泰格医药",
                    "员工持股",
                    "非交易过户"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "original_text": "泰格医药(300347.SZ)：2020年A股员工持股计划完成非交易过户",
            "scores": {
                "News_content": "泰格医药(300347.SZ)：2020年A股员工持股计划完成非交易过户",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "orginal_text": "抱团股爆发，沪指重上3500！创业板次新股最猛飙100%",
            "features": {
                "keywords": [
                    "抱团股",
                    "沪指",
                    "创业板",
                    "次新股"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "综合"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "抱团股爆发，沪指重上3500！创业板次新股最猛飙100%",
            "scores": {
                "News_content": "抱团股爆发，沪指重上3500！创业板次新股最猛飙100%",
                "Correlation": 4,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "orginal_text": "高瓴资本概念股普遍活跃，泰格医药、国瓷材料、甘李药业、恩捷股份大涨",
            "features": {
                "keywords": [
                    "高瓴资本",
                    "泰格医药",
                    "国瓷材料",
                    "甘李药业",
                    "恩捷股份"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "材料"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "高瓴资本概念股普遍活跃，泰格医药、国瓷材料、甘李药业、恩捷股份大涨",
            "scores": {
                "News_content": "高瓴资本概念股普遍活跃，泰格医药、国瓷材料、甘李药业、恩捷股份大涨",
                "Correlation": 8,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 7,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "orginal_text": "【异动股】泰格医药(03347-HK)涨5.51%",
            "features": {
                "keywords": [
                    "泰格医药",
                    "异动股"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "【异动股】泰格医药(03347-HK)涨5.51%",
            "scores": {
                "News_content": "【异动股】泰格医药(03347-HK)涨5.51%",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "orginal_text": "中金指泰格医药(03347-HK)海外业务有较强增长力首予目标价200港元",
            "features": {
                "keywords": [
                    "中金",
                    "泰格医药",
                    "海外业务",
                    "目标价"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "original_text": "中金指泰格医药(03347-HK)海外业务有较强增长力首予目标价200港元",
            "scores": {
                "News_content": "中金指泰格医药(03347-HK)海外业务有较强增长力首予目标价200港元",
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "orginal_text": "中泰证券--泰格医药：主业加速恢复，全球布局有望逐步推进【公司研究】",
            "features": {
                "keywords": [
                    "中泰证券",
                    "泰格医药",
                    "主业恢复",
                    "全球布局"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "original_text": "中泰证券--泰格医药：主业加速恢复，全球布局有望逐步推进【公司研究】",
            "scores": {
                "News_content": "中泰证券--泰格医药：主业加速恢复，全球布局有望逐步推进【公司研究】",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "orginal_text": "医药生物行业报告简版：药品集采常态化推进 看好创新主线、API+制剂一体化龙头企业",
            "features": {
                "keywords": [
                    "医药生物",
                    "药品集采",
                    "创新",
                    "API+制剂"
                ],
                "sentiment_score": 0.65,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "original_text": "医药生物行业报告简版：药品集采常态化推进 看好创新主线、API+制剂一体化龙头企业",
            "scores": {
                "News_content": "医药生物行业报告简版：药品集采常态化推进 看好创新主线、API+制剂一体化龙头企业",
                "Correlation": 6,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 8,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        }
    ]
]